OKUR

Rating neutralTentativeAI Memo

OnKure Therapeutics

As of 2026-10-09/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

Planned OKI-355 IND submission • 2027-06-30

Base target: $2 / p=0% prob

Biggest risk

IND delays, regulatory questions or higher development spending could weigh heavily on a small-cap stock before clinical evidence emerges. The August 7 option repricing also raises an incentive-governance question, though the filing says it did not change the options' underlying share counts [#8-K-2026-08-13].

Invalidation

Break below $1 or thesis failure.

What would change my mind?

Timely progress toward two distinct IND submissions, backed by the reported cash runway, could improve confidence in the pipeline. This remains a development-stage thesis, not a demonstrated efficacy thesis.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-10-09

Base target

p=0%

Bull target

p=0%

Bear target

p=0%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway through planned development milestones
Timely progress toward two distinct IND submissions, backed by the reported cash runway, could improve confidence in the pipeline.
This remains a development-stage thesis, not a demonstrated efficacy thesis.

BearKey bullets

Neither OKI-355 nor OKI-345 has patient-level safety or efficacy evidence in the supplied materials; planned IND submissions can slip or draw regulatory questions.
R&D expense was $12.6 million in second-quarter 2026; the runway estimate depends on future spending and development plans [#SEC-8K-2026-08-04].
The August 2026 repricing of certain underwater employee and executive options warrants governance monitoring [#8-K-2026-08-13].

WatchKey bullets

Planned OKI-355 IND submission

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $2 (p=0%)

Target spread vs base: +90% / -45%

Scenario probabilities

Bull Target: $4 (p=0%)Base Target: $2 (p=0%)Bear Target: $1 (p=0%)

Commentary

The SEC-filed August earnings exhibit supports the program timelines, expenses and runway, but the packet provides no recent trusted-news set, verified post-release price reaction, consensus surprise or analyst revisions [#SEC-8K-2026-08-04]. Zero-valued sentiment fields indicate unavailable measurements, not neutral observations. The negative deterministic directional prior, limited clinical visibility and lack of comparable small-cap equity peers support a cautious monitoring view.

As of 2026-10-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway through planned development milestones

Scenarios

Bull Target (Scenario probability)

$4 / p=0% prob

Base Target (Scenario probability)

$2 / p=0% prob

Bear Target (Scenario probability)

$1 / p=0% prob

Analysis 2026-10-09 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-06-30
Planned OKI-355 IND submission
OnKure plans to submit an FDA investigational new drug application for its vascular-anomalies candidate in the first half of 2027. Submission would advance the program but would not establish clinical safety or efficacy [#SEC-8K-2026-08-04].
Prob 60.00% • Move 30.00% • Priced-in 35.00%
EVENT2027-06-30
Planned OKI-345 IND submission
OnKure separately plans a first-half 2027 FDA IND submission for its breast-cancer candidate. Timing and regulatory execution remain uncertain; the supplied evidence contains no patient-level results for this candidate [#SEC-8K-2026-08-04].
Prob 60.00% • Move 25.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Runway through planned development milestones
2027-06-30
OnKure reported $176.4 million of cash, cash equivalents and marketable securities at June 30, 2026, and expects funding into 2029. Spending against that plan matters as both candidates progress through IND-enabling work [#SEC-8K-2026-08-04].
Prob 75% • Move 10% • Priced-in 70%

Risks

Neither OKI-355 nor OKI-345 has patient-level safety or efficacy evidence in the supplied materials; planned IND submissions can slip or draw regulatory questions.
R&D expense was $12.6 million in second-quarter 2026; the runway estimate depends on future spending and development plans [#SEC-8K-2026-08-04].
The August 2026 repricing of certain underwater employee and executive options warrants governance monitoring [#8-K-2026-08-13].
The identified PI3Kα program benchmarks are at later development stages or embedded in a diversified company, limiting their use for OKUR equity valuation.

Peers

Symbol	Summary
RLAY	Relay's zovegalisib is a mutant-selective PI3Kα program studied in both breast cancer and vascular anomalies, making it a direct scientific benchmark. Its breast-cancer program is already in Phase 3, far ahead of OnKure's planned IND submissions, so its equity valuation is not directly transferable. Source: https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-data-zovegalisib-fulvestrant-phase
NVS	Novartis announced a March 2026 agreement to acquire a portfolio including SNV4818, a pan-mutant-selective PI3Kα inhibitor already in Phase 1/2 for breast cancer and other solid tumors. The announcement does not establish that the acquisition closed. This is a relevant program benchmark, not a small-cap equity valuation peer. Source: https://www.novartis.com/news/media-releases/novartis-agrees-acquire-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-09

Loading AI feed…

Symbol

Summary

RLAY

Relay's zovegalisib is a mutant-selective PI3Kα program studied in both breast cancer and vascular anomalies, making it a direct scientific benchmark. Its breast-cancer program is already in Phase 3, far ahead of OnKure's planned IND submissions, so its equity valuation is not directly transferable. Source: https://ir.relaytx.com/news-releases/news-release-details/relay-therapeutics-announces-data-zovegalisib-fulvestrant-phase

NVS

Novartis announced a March 2026 agreement to acquire a portfolio including SNV4818, a pan-mutant-selective PI3Kα inhibitor already in Phase 1/2 for breast cancer and other solid tumors. The announcement does not establish that the acquisition closed. This is a relevant program benchmark, not a small-cap equity valuation peer. Source: https://www.novartis.com/news/media-releases/novartis-agrees-acquire-pan-mutant-selective-pi3ka-inhibitor-strengthening-its-breast-cancer-pipeline